Blueprint Medicines (NASDAQ:BPMC) Releases Earnings Results, Misses Expectations By $0.11 EPS

Blueprint Medicines (NASDAQ:BPMC) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11), Zacks reports. Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%.

Blueprint Medicines Price Performance

NASDAQ BPMC traded up $1.88 during trading hours on Thursday, reaching $95.95. 222,326 shares of the company’s stock were exchanged, compared to its average volume of 1,015,968. The stock has a market cap of $6.13 billion, a PE ratio of -88.93 and a beta of 0.62. Blueprint Medicines has a one year low of $80.42 and a one year high of $121.90. The firm has a fifty day moving average of $99.53 and a 200-day moving average of $94.40. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, CEO Kate Haviland sold 2,353 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $96.60, for a total value of $227,299.80. Following the transaction, the chief executive officer now directly owns 150,824 shares in the company, valued at approximately $14,569,598.40. This trade represents a 1.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Christina Rossi sold 2,274 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.14, for a total value of $250,458.36. Following the completion of the transaction, the chief operating officer now owns 67,109 shares in the company, valued at $7,391,385.26. The trade was a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 49,851 shares of company stock worth $4,984,696. Insiders own 4.21% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a report on Friday, February 14th. Wells Fargo & Company lowered their target price on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Guggenheim reiterated a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. Needham & Company LLC reiterated a “buy” rating and set a $133.00 price target on shares of Blueprint Medicines in a research note on Thursday, February 13th. Finally, Wedbush reissued an “outperform” rating and set a $128.00 price objective (up previously from $124.00) on shares of Blueprint Medicines in a research report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Blueprint Medicines has a consensus rating of “Moderate Buy” and an average target price of $123.83.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.